• Focus Areas
    • Cause Selection
    • Global Health & Wellbeing
      • Effective Altruism (Global Health and Wellbeing)
      • Farm Animal Welfare
      • Global Aid Policy
      • Global Health & Development
      • Global Health R&D
      • Innovation Policy
      • Land Use Reform
      • Scientific Research
      • South Asian Air Quality
    • Global Catastrophic Risks
      • Biosecurity & Pandemic Preparedness
      • Global Catastrophic Risks Capacity Building
      • Potential Risks from Advanced AI
    • Other Areas
      • Criminal Justice Reform
      • History of Philanthropy
      • Immigration Policy
      • Macroeconomic Stabilization Policy
  • Grants
  • Research & Updates
    • Research Reports
    • Blog Posts
    • Notable Lessons
    • In the News
  • About Us
    • Grantmaking Process
    • How to Apply for Funding
    • Team
    • Contact Us
    • Stay Updated
  • We’re hiring!
  • Focus Areas
    • Cause Selection
    • Global Health & Wellbeing
      • Effective Altruism (Global Health and Wellbeing)
      • Farm Animal Welfare
      • Global Aid Policy
      • Global Health & Development
      • Global Health R&D
      • Innovation Policy
      • Land Use Reform
      • Scientific Research
      • South Asian Air Quality
    • Global Catastrophic Risks
      • Biosecurity & Pandemic Preparedness
      • Global Catastrophic Risks Capacity Building
      • Potential Risks from Advanced AI
    • Other Areas
      • Criminal Justice Reform
      • History of Philanthropy
      • Immigration Policy
      • Macroeconomic Stabilization Policy
  • Grants
  • Research & Updates
    • Research Reports
    • Blog Posts
    • Notable Lessons
    • In the News
  • About Us
    • Grantmaking Process
    • How to Apply for Funding
    • Team
    • Contact Us
    • Stay Updated
  • We’re hiring!

Schepens Eye Research Institute at Mass Eye and Ear — Pulmonary Fibrosis Drug (Leo Kim)

Visit Grantee Site
  • Focus Area: Scientific Research
  • Organization Name: Mass Eye and Ear
  • Amount: $920,000

  • Award Date: July 2021

Table of Contents

    Open Philanthropy recommended a grant of $920,000 to Mass Eye and Ear to support research led by Leo Kim, of Mass Eye and Ear and Harvard Medical School, on a drug to treat pulmonary fibrosis in patients with COVID-19 and other causes. Pulmonary fibrosis is a chronic and often fatal lung disease that affects approximately 3.5 million people worldwide, in addition to a significant number of patients hospitalized with COVID-19.

    This falls within our work on scientific research, specifically within our interest in human health and wellbeing.

    Related Items

    • Scientific Research

      University of California, San Francisco Foundation — Reproductive Medicine Research (2023)

      Open Philanthropy recommended a gift of $200,000 over 2.5 years to the University of California, San Francisco (UCSF) Foundation to support research led by Professor Paolo Rinaudo on...

      Read more
    • Scientific Research

      CDC Foundation — Malaria Control Research Project (2023)

      Open Philanthropy recommended a grant of $900,000 over two years to the CDC Foundation to support research on malaria control. The funding will be used to support work...

      Read more
    • Scientific Research

      University of Edinburgh — Preterm Birth RCT

      Open Philanthropy recommended a grant of $344,973 to the University of Edinburgh over 1.5 years to support a randomized controlled trial on a combination treatment (aspirin, a vitamin...

      Read more
    Back to Grants Database
    Open Philanthropy
    Open Philanthropy
    • Careers
    • Press Kit
    • Governance
    • Privacy Policy
    • Stay Updated
    Mailing Address
    Open Philanthropy
    182 Howard Street #225
    San Francisco, CA 94105
    Email
    [email protected]
    Media Inquiries
    [email protected]
    Anonymous Feedback
    Feedback Form

    © Open Philanthropy 2022 Except where otherwise noted, this work is licensed under a Creative Commons Attribution-Noncommercial 4.0 International License. If you'd like to translate this content into another language, please get in touch!